These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18437428)

  • 21. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Etiology, diagnostics and therapy of hyponatremias].
    Laczi F
    Orv Hetil; 2008 Jul; 149(29):1347-54. PubMed ID: 18617466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia.
    Kalra S; Efrati S; Arthur JM; Oliven A; Velez JC; McNutt BE; Klasen S; Abeyratne A
    Am J Health Syst Pharm; 2011 Apr; 68(7):590-8. PubMed ID: 21411800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet.
    Gross PA; Wagner A; Decaux G
    Kidney Int; 2011 Sep; 80(6):594-600. PubMed ID: 21451459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
    Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
    Rollino C; Balbiano R; Caramello P; Roccatello D
    G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.
    Koren MJ; Hamad A; Klasen S; Abeyratne A; McNutt BE; Kalra S
    Am J Health Syst Pharm; 2011 May; 68(9):818-27. PubMed ID: 21515866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Syndrome of inappropriate antidiuresis without involving inappropriate secretion of vasopressin in an elderly woman: effect of intravenous administration of the nonpeptide vasopressin V2 receptor antagonist OPC-31260.
    Kamoi K
    Nephron; 1997; 76(1):111-5. PubMed ID: 9171309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
    Ali F; Raufi MA; Washington B; Ghali JK
    Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.
    Palmer BF; Rock AD; Woodward EJ
    Drug Des Devel Ther; 2016; 10():339-51. PubMed ID: 26848258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and management of hyponatremia in cancer patients.
    Raftopoulos H
    Support Care Cancer; 2007 Dec; 15(12):1341-7. PubMed ID: 17701059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conivaptan therapy in an infant with severe hyponatremia and congestive heart failure.
    Sahu R; Balaguru D; Thapar V; Haque I; Pham-Peyton C; Bricker JT
    Tex Heart Inst J; 2012; 39(5):724-6. PubMed ID: 23109779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Vasopressin receptor antagonists: the vaptans].
    Villabona C
    Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients.
    Marik PE; Rivera R
    Pharmacotherapy; 2013 Jan; 33(1):51-5. PubMed ID: 23307545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
    Der-Nigoghossian C; Lesch C; Berger K
    Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extreme correction of hyponatremia in a patient treated with intravenous conivaptan.
    Sughrue ME; McDermott M; Blevins LS
    J Clin Neurosci; 2010 Oct; 17(10):1331-4. PubMed ID: 20594854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [From hyponatremia to tolvaptan].
    Cernaro V; Santoro D; Lacquaniti A; Montalto G; Buemi M
    G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Syndrome of inadequate ADH secretion: pitfalls in diagnosis and therapy].
    Schäffler A; Lindner U
    Dtsch Med Wochenschr; 2015 Mar; 140(5):343-6. PubMed ID: 25734677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The treament of hyponatremia secundary to the syndrome of inappropriate antidiuretic hormone secretion].
    Runkle I; Villabona C; Navarro A; Pose A; Formiga F; Tejedor A; Poch E;
    Med Clin (Barc); 2013 Dec; 141(11):507.e1-507.e10. PubMed ID: 24169317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats.
    Kazama I; Hatano R; Michimata M; Suzuki K; Arata T; Suzuki M; Miyama N; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
    Kidney Int; 2005 May; 67(5):1855-67. PubMed ID: 15840033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.